A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-15 | actual | When the study began enrolling |
| Primary completion | 2026-08-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-05 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Hepatic Impairment
Intervention
- Drug: BMS-986435 — also filed as MYK-224
Primary outcomes
what the primary-completion date above is the date OFMaximum observed concentration (Cmax)
measured Up to Day 45
Area under the concentration-time curve from time zero to time of last quantifiable concentration AUC(0-T)
measured Up to Day 45
Area under the concentration-time curve from time zero extrapolated to infinite time AUC(INF)
measured Up to Day 45
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed